Filtering by:
FDAFDA Approves Keytruda (Pembrolizumab) for Head and Neck Cancer
The US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line treatment for people with advanced head and neck cancer.
FDA Approves Polivy (Polatuzumab Vedotin-piiq) for Lymphoma
The US Food and Drug Administration (FDA) has approved the antibody-drug conjugate Polivy (polatuzumab vedotin-piiq) to treat people with diffuse large B-cell lymphoma (DLBCL).
FDA Approves First PI3K Inhibitor for Breast Cancer
The US Food and Drug Administration (FDA) has approved the first treatment of its kind for a certain type of breast cancer caused by an inherited genetic mutation. Piqray (alpelisib) is a targeted therapy called a PI3K inhibitor.
FDA Approves First Targeted Therapy for Bladder Cancer
The US Food and Drug Administration (FDA) has approved Balversa (erdafitinib) as the first targeted therapy for bladder cancer.
FDA Approves Tecentriq (Atezolizumab) for Small Cell Lung Cancer
The US Food and Drug Administration (FDA) has approved the immunotherapy drug Tecentriq (atezolizumab) for the treatment of small cell lung cancer (SCLC).
FDA Approves Immunotherapy for Breast Cancer
The US Food and Drug Administration today approved the first immunotherapy treatment for breast cancer. It approved a combination of Tecentriq (atezolizumab) and Abraxane (nab-paclitaxel) for people with advanced triple negative breast cancer.
2018 in Review: New Cancer Drug Approvals
In 2018, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
FDA Approves First Biosimilar for Non-Hodgkin Lymphoma
The US Food and Drug Administration (FDA) has approved Truxima (rituximab-abbs), the first biosimilar drug to treat adults with some types of non-Hodgkin lymphoma.
